We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
JANX Stock Hits Record High on Prostate Cancer Study Data
Read MoreHide Full Article
Shares of Janux Therapeutics (JANX - Free Report) surged 49% on Tuesday after the company posted updated interim results from a phase Ib study, which is evaluating JANX007 in patients with advanced or metastatic prostate cancer (mCRPC).
The study enrolled mCRPC patients who were heavily pretreated with a median of four prior lines of therapy. As of the cut-off date of Nov. 15, 2024, 16 patients had been treated with once-weekly JANX007 doses ranging from 2 mg to 9 mg. None of these patients had been treated with Pluvicto, Novartis’ blockbuster prostate cancer therapy.
Data from the study showed that after 12 weeks of treatment with JANX007, all 16 patients achieved a 50% decline in prostate-specific antigen (PSA). PSA is a protein produced by cells of the prostate gland, too much of which is an indication of cancer. Treatment with the drug also demonstrated a favorable safety profile.
Of the 16 patients, 10 achieved a 90% reduction in PSA levels, with five experiencing a decline of 99%. Management also highlighted the sustained PSA reductions, noting that 75% of patients with a 50% decline maintained it for at least 12 weeks. Similarly, 50% of patients who achieved a 90% PSA decline maintained their reductions for the same duration.
Based on the above results, two once-weekly step-dose regimens of JANX007 have been selected for phase Ib expansion studies. These studies will enroll previously treated mCRPC patients who are yet to receive Pluvicto. Janux expects to provide an update on the drug next year.
JANX Stock’s Performance
Following the news, shares of Janux hit an all-time high of $71.25. Wall Street has been paying a lot of attention to the stock, thanks to the impressive clinical performance of JANX007. Management had previously provided an update on the above study earlier in February, where it claimed that 56% of the study participants who received the drug achieved a decline of 50% in PSA levels.
With this latest announcement, investors were likely impressed as the company’s drug efficacy surpassed the company’s last reported data. Several Wall Street analysts also praised the results, one even calling it ‘unprecedented.’ This is a likely reason for the share price soaring to an all-time high.
Year to date, Janux Therapeutics’ shares have soared 457.9% against the industry’s 7.0% decline.
Image Source: Zacks Investment Research
Why VIR Stock Rose on JANX News
Post Janux’s encouraging update on JANX007, shares of Vir Biotechnology (VIR) also rose 13% on Tuesday. Vir is also developing VIR-5500, a drug that is similar to JANX007.
VIR-5500 is currently being evaluated in an early-stage dose escalation study in mCRPC patients. Vir Biotechnology expects to provide an update in the first quarter of 2025.
JANX’s Zacks Rank
Janux Therapeutics currently carries a Zacks Rank #4 (Sell).
In the past 60 days, estimates for Castle Biosciences’ 2024 loss per share have narrowed from 58 cents to 8 cents. During the same timeframe, loss per share estimates for 2025 have narrowed from $2.13 to $1.88. Year to date, shares of Castle Biosciences have surged 42.6%.
CSTL’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 172.72%.
In the past 60 days, estimates for Spero Therapeutics’ 2024 loss per share have narrowed from $1.59 to $1.13. Estimates for 2025 loss per share have narrowed from $1.54 to 54 cents. Year to date, shares of Spero Therapeutics have lost 21.1%.
Spero Therapeutics’ earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 94.42%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
JANX Stock Hits Record High on Prostate Cancer Study Data
Shares of Janux Therapeutics (JANX - Free Report) surged 49% on Tuesday after the company posted updated interim results from a phase Ib study, which is evaluating JANX007 in patients with advanced or metastatic prostate cancer (mCRPC).
The study enrolled mCRPC patients who were heavily pretreated with a median of four prior lines of therapy. As of the cut-off date of Nov. 15, 2024, 16 patients had been treated with once-weekly JANX007 doses ranging from 2 mg to 9 mg. None of these patients had been treated with Pluvicto, Novartis’ blockbuster prostate cancer therapy.
Data from the study showed that after 12 weeks of treatment with JANX007, all 16 patients achieved a 50% decline in prostate-specific antigen (PSA). PSA is a protein produced by cells of the prostate gland, too much of which is an indication of cancer. Treatment with the drug also demonstrated a favorable safety profile.
Of the 16 patients, 10 achieved a 90% reduction in PSA levels, with five experiencing a decline of 99%. Management also highlighted the sustained PSA reductions, noting that 75% of patients with a 50% decline maintained it for at least 12 weeks. Similarly, 50% of patients who achieved a 90% PSA decline maintained their reductions for the same duration.
Based on the above results, two once-weekly step-dose regimens of JANX007 have been selected for phase Ib expansion studies. These studies will enroll previously treated mCRPC patients who are yet to receive Pluvicto. Janux expects to provide an update on the drug next year.
JANX Stock’s Performance
Following the news, shares of Janux hit an all-time high of $71.25. Wall Street has been paying a lot of attention to the stock, thanks to the impressive clinical performance of JANX007. Management had previously provided an update on the above study earlier in February, where it claimed that 56% of the study participants who received the drug achieved a decline of 50% in PSA levels.
With this latest announcement, investors were likely impressed as the company’s drug efficacy surpassed the company’s last reported data. Several Wall Street analysts also praised the results, one even calling it ‘unprecedented.’ This is a likely reason for the share price soaring to an all-time high.
Year to date, Janux Therapeutics’ shares have soared 457.9% against the industry’s 7.0% decline.
Image Source: Zacks Investment Research
Why VIR Stock Rose on JANX News
Post Janux’s encouraging update on JANX007, shares of Vir Biotechnology (VIR) also rose 13% on Tuesday. Vir is also developing VIR-5500, a drug that is similar to JANX007.
VIR-5500 is currently being evaluated in an early-stage dose escalation study in mCRPC patients. Vir Biotechnology expects to provide an update in the first quarter of 2025.
JANX’s Zacks Rank
Janux Therapeutics currently carries a Zacks Rank #4 (Sell).
Janux Therapeutics, Inc. Price
Janux Therapeutics, Inc. price | Janux Therapeutics, Inc. Quote
Key Picks Among Biotech Stocks
A couple of better-ranked stocks from the sector are Castle Biosciences (CSTL - Free Report) and Spero Therapeutics (SPRO - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for Castle Biosciences’ 2024 loss per share have narrowed from 58 cents to 8 cents. During the same timeframe, loss per share estimates for 2025 have narrowed from $2.13 to $1.88. Year to date, shares of Castle Biosciences have surged 42.6%.
CSTL’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 172.72%.
In the past 60 days, estimates for Spero Therapeutics’ 2024 loss per share have narrowed from $1.59 to $1.13. Estimates for 2025 loss per share have narrowed from $1.54 to 54 cents. Year to date, shares of Spero Therapeutics have lost 21.1%.
Spero Therapeutics’ earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 94.42%.